Key Sessions
Karina Thorn
Fireside chat: Novo Nordisk’s RNA Partnerships – 2024 Review and 2025 Outlook
Novo Nordisk
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Pre-Conference Day – Tuesday 4th March 2025 - CET (Central European Time, GMT+01:00)
keyboard_arrow_leftSearch & Filter
search
Streams
Formats
Pre-Conference Day – Tuesday 4th March 2025 - CET (Central European Time, GMT+01:00)
search
Streams
Formats
12:00 - 13:0060 mins
Registration
13:00 - 13:5050 mins
General Session
Navigating Regulatory Framework for RNA Therapeutics & Next-Generation Vaccines across Europe
- Shirley Hopper - Deputy Director National Licensing Strategy, MHRA
13:50 - 15:2090 mins
General Session
Tissue Targeting - Deep dive into targeted delivery of mRNA and Oligo-based therapeutics to various tissue types
- Marty Koser - Head of Platform Innovation, Global Nucleic Acid Therapies Research, Novo Nordisk
- Manuel Vega - CEO, AGS Therapeutics
15:20 - 15:4020 mins
Afternoon Break
15:40 - 16:3050 mins
General Session
Scaling RNA Modalities to the Clinic
16:30 - 17:1545 mins
General Session
Fireside chat: Novo Nordisk’s RNA Partnerships – 2024 Review and 2025 Outlook
- Karina Thorn - Corporate Vice President, Head of Research, Global Nucleic Acid Therapies Research, Novo Nordisk
17:15 - 18:1560 mins
Close of Pre-Conference Day and Networking Reception
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Formats